Green Cross Holdings Preference Shares (005257) - Net Assets

Latest as of March 2026: ₩1.72 Trillion KRW ≈ $1.17 Billion USD

Based on the latest financial reports, Green Cross Holdings Preference Shares (005257) has net assets worth ₩1.72 Trillion KRW (≈ $1.17 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩4.12 Trillion ≈ $2.79 Billion USD) and total liabilities (₩2.40 Trillion ≈ $1.63 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Green Cross Holdings Preference Shares assets under control for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩1.72 Trillion
% of Total Assets 41.75%
Annual Growth Rate 4.02%
5-Year Change -7.69%
10-Year Change 28.09%
Growth Volatility 5.77

Green Cross Holdings Preference Shares - Net Assets Trend (2013–2025)

This chart illustrates how Green Cross Holdings Preference Shares's net assets have evolved over time, based on quarterly financial data. Check how tangible is Green Cross Holdings Preference Shares's equity to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Green Cross Holdings Preference Shares (2013–2025)

The table below shows the annual net assets of Green Cross Holdings Preference Shares from 2013 to 2025. For live valuation and market cap data, see market cap of Green Cross Holdings Preference Shares.

Year Net Assets Change
2025-12-31 ₩1.76 Trillion
≈ $1.20 Billion
-4.77%
2024-12-31 ₩1.85 Trillion
≈ $1.26 Billion
-1.56%
2023-12-31 ₩1.88 Trillion
≈ $1.28 Billion
-4.35%
2022-12-31 ₩1.97 Trillion
≈ $1.33 Billion
+2.95%
2021-12-31 ₩1.91 Trillion
≈ $1.29 Billion
+14.18%
2020-12-31 ₩1.67 Trillion
≈ $1.13 Billion
+11.08%
2019-12-31 ₩1.51 Trillion
≈ $1.02 Billion
+3.68%
2018-12-31 ₩1.45 Trillion
≈ $984.76 Million
+0.93%
2017-12-31 ₩1.44 Trillion
≈ $975.64 Million
+4.55%
2016-12-31 ₩1.38 Trillion
≈ $933.18 Million
+5.33%
2015-12-31 ₩1.31 Trillion
≈ $885.99 Million
+10.69%
2014-12-31 ₩1.18 Trillion
≈ $800.39 Million
+7.40%
2013-12-31 ₩1.10 Trillion
≈ $745.23 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Green Cross Holdings Preference Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 39.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings ₩806.79 Billion 89.55%
Other Components ₩94.14 Billion 10.45%
Total Equity ₩900.93 Billion 100.00%

Green Cross Holdings Preference Shares Competitors by Market Cap

The table below lists competitors of Green Cross Holdings Preference Shares ranked by their market capitalization.

Company Market Cap
Olivers Real Food Ltd
AU:OLI
$2.30 Million
Appulse Corp
V:APL
$2.30 Million
China Aoyuan Group Limited
F:47C
$2.30 Million
Erayak Power Solution Group Inc. Class A Ordinary Shares
NASDAQ:RAYA
$2.30 Million
Amedeo Air Four Plus Limited
LSE:AA4
$2.29 Million
Volta Finance Ltd
LSE:VTAS
$2.29 Million
MPAY S.A. ZY-50
F:8NJ
$2.29 Million
Easson Holdings Ltd
PA:MLEAS
$2.29 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Green Cross Holdings Preference Shares's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 994,091,218,410 to 900,929,806,590, a change of -93,161,411,820 (-9.4%).
  • Net loss of 69,512,977,040 reduced equity.
  • Dividend payments of 33,206,604,450 reduced retained earnings.
  • New share issuances of 536,457,270 increased equity.
  • Other factors increased equity by 9,021,712,400.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ₩-69.51 Billion -7.72%
Dividends Paid ₩33.21 Billion -3.69%
Share Issuances ₩536.46 Million +0.06%
Other Changes ₩9.02 Billion +1.0%
Total Change ₩- -9.37%

Book Value vs Market Value Analysis

This analysis compares Green Cross Holdings Preference Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.71x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 ₩18088.90 ₩14070.00 x
2018-12-31 ₩17900.56 ₩14070.00 x
2019-12-31 ₩18089.53 ₩14070.00 x
2020-12-31 ₩20458.83 ₩14070.00 x
2021-12-31 ₩22820.59 ₩14070.00 x
2022-12-31 ₩23094.53 ₩14070.00 x
2023-12-31 ₩21815.28 ₩14070.00 x
2024-12-31 ₩22123.27 ₩14070.00 x
2025-12-31 ₩19943.17 ₩14070.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Green Cross Holdings Preference Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -7.72%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -2.84%
  • • Asset Turnover: 0.60x
  • • Equity Multiplier: 4.52x
  • Recent ROE (-7.72%) is below the historical average (4.15%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 6.48% 4.64% 0.58x 2.42x ₩-23.64 Billion
2014 8.07% 5.43% 0.58x 2.55x ₩-13.58 Billion
2015 8.95% 5.77% 0.55x 2.82x ₩-7.67 Billion
2016 6.11% 3.48% 0.60x 2.92x ₩-29.98 Billion
2017 5.34% 2.96% 0.57x 3.15x ₩-37.92 Billion
2018 2.30% 1.19% 0.59x 3.27x ₩-61.97 Billion
2019 0.36% 0.19% 0.55x 3.41x ₩-78.33 Billion
2020 18.60% 9.94% 0.53x 3.53x ₩79.03 Billion
2021 5.39% 3.00% 0.53x 3.41x ₩-47.27 Billion
2022 3.16% 1.58% 0.58x 3.46x ₩-70.95 Billion
2023 -5.52% -2.63% 0.55x 3.81x ₩-152.16 Billion
2024 2.42% 1.09% 0.60x 3.69x ₩-75.38 Billion
2025 -7.72% -2.84% 0.60x 4.52x ₩-159.61 Billion

Industry Comparison

This section compares Green Cross Holdings Preference Shares's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $71,499,919,473
  • Average return on equity (ROE) among peers: -16.90%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Green Cross Holdings Preference Shares (005257) ₩1.72 Trillion 6.48% 1.40x $2.29 Million
ORIENTBIO Inc. (002630) $44.21 Billion 0.00% 0.54x $71.52 Million
Green Cross (005250) $210.22 Billion 1.73% 6.63x $283.20 Million
Pharmicell (005690) $63.87 Billion 14.80% 0.48x $411.92 Million
GeneOne Life Science Inc (011000) $40.90 Billion -126.78% 1.91x $164.07 Million
HLB Co. Ltd (028300) $174.68 Billion 14.51% 0.74x $2.76 Billion
Mgenplus Co. Ltd. (032790) $10.14 Billion -54.19% 2.17x $16.13 Million
Daesung Microbiological Labs. Co. Ltd (036480) $35.42 Billion 1.69% 0.64x $15.71 Million
Seoulin Bioscience Co.Ltd (038070) $41.57 Billion 10.01% 0.45x $24.62 Million
Hyundai Bioscience Co. Ltd (048410) $22.49 Billion -13.82% 0.46x $384.00 Million

About Green Cross Holdings Preference Shares

KO:005257 Korea Biotechnology
Market Cap
$2.29 Million
₩3.39 Billion KRW
Market Cap Rank
#29830 Global
#2098 in Korea
Share Price
₩14070.00
Change (1 day)
+0.50%
52-Week Range
₩13800.00 - ₩31000.00
All Time High
₩250917.65
About

GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and… Read more